UK FTF - Funds signed to date

Advent Venture Partners www.adventventures.com

Advent Venture Partners is one of Europe’s most established growth and venture capital firms, investing in technology and life sciences businesses run by great teams that want a pragmatic and well-connected partner by their side.

The Advent life sciences team is a leader in European life sciences venture capital.  Its investments  include: PowderMed, a therapeutic DNA vaccine company sold to Pfizer; Thiakis, an obesity treatment company acquired by Wyeth Pharmaceuticals; Respivert, a drug discovery company focused on respiratory diseases that was acquired by Johnson & Johnson; Cellnovo, a biomedical device company developing a revolutionary mobile insulin pump system; EUSA Pharma, a rapidly growing transatlantic speciality pharmaceutical company focused on late-stage oncology, pain control and critical care products; and, Algeta (ALGETA.OL), an oncology company developing treatments for bone metastases and disseminated tumour types.

Press Release

Heureka Growth Fund www.actoncapital.de

The Fund which is managed by Munich-based Acton Capital Partners targets industry leading growth stage companies in the internet and mobile communications sector. The Fund focuses on consumer-oriented business models in e-commerce, media and marketplaces, mainly within Europe but also in North America. The team has a long record of investing in the most exciting high growth potential early and expansion stage technology companies.

Press Release

DFJ Esprit III  http://www.dfjesprit.com/home

DFJ Esprit III is top tier, cross-stage European venture capital firm DFJ Esprit's third primary venture fund and will be focused on investing in the most exciting early and later stage technology companies in the UK and across Europe. DFJ Esprit is the exclusive European partner for Silicon Valley based Draper Fisher Jurvetson (DFJ) Global Network of venture funds, the largest venture capital network in the world with $6bn under management and offices in 30 cities spanning four continents. DFJ Esprit also has a separate secondary division, Encore Ventures, which acquired 3i's European venture portfolio in 2009. The UK FTF investment is solely for new primary investing through the DFJ Esprit III fund.

Press release

Gilde Healthcare III   http://www.gildehealthcare.nl

Gilde Healthcare III is managed by Netherlands-based Gilde Healthcare Partners B.V and will target late stage venture capital investments. At least one third of the fund will be directed towards investments in home healthcare solutions with other investments in medical technologies/diagnostics and therapeutics.

SEP IV     http://www.sep.co.uk

The Glasgow based Scottish Equity Partner’s latest fund, SEP IV provides an excellent fit with the stage and sector targets, with a major focus on investments in the ICT, Healthcare and Energy sectors in the UK.

The team managing the fund has been involved in SME financing for a significant part of the last two decades and has amassed strong market knowledge and peer recognition as one of the most consistent and established players in the UK venture capital market